Diabetes (type 2) - canagliflozin: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Evaluation report:
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Association of British Clinical Diabetologists
03. Commentator comments on the ACD - AstraZeneca
04. Commentator comments on the ACD - Department of Health
05. Consultee comments on the ACD - Janssen
06. Commentator comments on the ACD - Lilly UK
07. Commentator comments on the ACD - Merck Sharp & Dohme
08. Commentator comments on the ACD - Novo Nordisk
09. Consultee comments on the ACD - Royal College of Physicians
10. Consultee comments on the ACD - Royal College of Nursing
Diabetes (type 2) - canagliflozin: evaluation report
16 May 2014 (2.06 Mb 14 sec) |
This page was last updated: 14 May 2014